Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-803 Relapse Prophylaxis in AML and MDS Post-Transplant
NCT02989844Phase 2Completed
- Sponsor
- Masonic Cancer Center
- Start
- Apr 2017
- Primary completion
- Mar 2022
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nogapendekin alfa inbakicept in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Masonic Cancer Center. Primary endpoint: Incidence of Relapse at 24 months. Started Apr 2017; status: completed.
02
Drugs
nogapendekin alfa inbakicept
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02989844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02989844.